BartoszChmielowskiMDPhD
Oncology • Los Angeles, CAHematologic Oncology, Melanoma, Sarcoma
Associate Professor, Medicine, UCLA School of Medicine
Dr. Chmielowski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
100 UCLA Medical Plaza
Suite 550
Los Angeles, CA 90095Phone+1 310-794-4955Fax+1 310-794-4955
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Medical College of GeorgiaResidency, Internal Medicine, 2001 - 2005
Wroclaw Medical UniversityClass of 1995
Certifications & Licensure
CA State Medical License 2004 - 2026
GA State Medical License 2004 - 2005- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors:LA Area Castle Connolly, 2013
- Top Doctors:Southern California Castle Connolly, 2012
Clinical Trials
- Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2007 Apr 01
- A Phase I/II Study of Daily Oral Dosing With Temozolomide and Sunitinib Malate for 6 Weeks of an 8-Week Cycle in Patients With Metastatic and Unresectable Locally-Advanced Malignant Melanoma Start of enrollment: 2009 Apr 01
- Study of Gene Modified Immune Cells in Patients With Advanced Melanoma Start of enrollment: 2009 Oct 13
- Join now to see all
Publications & Presentations
PubMed
- Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC...Yvonne M Mowery, Karla V Ballman, Angela M Hong, Scott M Schuetze, Andrew J Wagner
Lancet. 2024-11-23 - 1 citationsThe landscape of drug sensitivity and resistance in sarcoma.Ahmad Al Shihabi, Peyton J Tebon, Huyen Thi Lam Nguyen, Jomjit Chantharasamee, Sara Sartini
Cell Stem Cell. 2024-10-03 - 7 citationsNCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024.Susan M Swetter, Douglas Johnson, Mark R Albertini, Christopher A Barker, Sarah Bateni
Journal of the National Comprehensive Cancer Network. 2024-07-01
Press Mentions
ASCO 2022 | Ascentage Pharma Releases Updated Results Demonstrating the Therapeutic Potential of Alrizomadlin (APG-115) plus Pembrolizumab in Patients with Solid Tumors Who Progressed on ImmunotherapiesJune 7th, 2022- Reversing Resistance to PD-1 Inhibitors with Combination Immunotherapy in Patients with Advanced MelanomaApril 8th, 2022
- Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021September 13th, 2021
- Join now to see all
Professional Memberships
- Member
Other Languages
- Polish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
